- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05884658
Histerectomía por orificio natural transvaginal Cirugía endoscópica transluminal versus histerectomía laparoscópica (vNOTESHC)
vNOTESHC: Histerectomía por cirugía endoscópica transluminal transvaginal con orificio natural versus histerectomía laparoscópica: un ensayo controlado aleatorizado
In France, there are approximately 62,000 hysterectomies per year, 70% of which are benign. It is the most frequent surgical procedure in gynecology.
Hysterectomies are performed via 3 routes: laparotomy, laparoscopy or vaginal route.
This choice of approach is particularly important in the case of large uteri (50% of uteri > 280g), which increase the risks of laparoconversion and bladder injury (NP3).
The vaginal route reduces the operating time and postoperative pain. Laparoscopy allows a better anatomical view and easier access to the neighbouring organs, which makes it the preferred approach, especially for young surgeons and when the uterus is large. However, the laparoscopic route is associated with an increase in the rate of conversion to laparotomy according to the volume of the uterus, as well as the rate of general per and postoperative complications compared with vaginal hysterectomy for uteri > 280 g. In a meta-analysis comparing laparoscopy and vaginal hysterectomy, the total prevalence of perioperative complications according to the classification of Clavien and Dindo was 27%. For large uteruses, complications by the vaginal route amounted to 15% and those by the laparoscopic route to 37.5%.
The data are not sufficient to give preference to one or other of the approaches, but for benign pathologies, for large uteri (>280 g), the minimally invasive laparoscopic or vaginal approaches are recommended by the CNGOF (grade C).
A new Medical Device (MD), the vNOTES (Vaginal Natural Orifice Transluminal Endoscopy System) offers the advantage of two approaches for pelvic surgery by allowing minimally invasive surgery to be performed by endoscopy through the vagina, offering perfect vision for the assistants and the operator and without scarring. Two randomized trials have shown that vNOTES allows, compared to laparoscopy, to perform adnexectomies and hysterectomies without conversion with less pain, fewer postoperative complications and a shorter hospitalization time.
The first evaluations of vNOTES are encouraging and suggest a new era for pelvic surgery: less postoperative pain, fewer complications and facilitation of ambulatory care. Also the videoscopic assistance of the vNOTES is a pedagogical tool for the vaginal route because the field of vision is no longer limited to the operator alone. However, the vNOTES has only been evaluated by the developers of the tool, in monocentric studies and in small numbers. The hysterectomy study evaluated only 35 patients with vNOTES, half of whom had a uterus of less than 280 g. The benefit of vNOTES for uteri smaller than 280 g is not obvious because of the ease of the surgical procedure and the cost of the "classic" vaginal route. Our study would be the first multicentric and academic study on vNOTES to focus specifically on large volume uteri, the most difficult to operate and prone to postoperative complications.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Florence RANCON
- Número de teléfono: +33 0477829458
- Correo electrónico: florence.rancon@chu-st-etienne.fr
Copia de seguridad de contactos de estudio
- Nombre: Céline CHAULEUR, PhD
- Número de teléfono: +33 0477828383
- Correo electrónico: celine.chauleur@chu-st-etienne.fr
Ubicaciones de estudio
-
-
-
Bron, Francia, 69677
- Aún no reclutando
- HFME - Hospices Civils de Lyon
-
Investigador principal:
- Géry LAMBLIN
-
Contacto:
- Géry LAMBLIN
- Correo electrónico: gery.lamlin@chu-lyon.fr
-
Clermont-Ferrand, Francia, 63003
- Reclutamiento
- CHU Clermont-Ferrand
-
Sub-Investigador:
- Sandra CURINIER, PH
-
Contacto:
- Sandrine CAMPAGNE-LOISEAU, PH
- Correo electrónico: scampagne-loiseau@chu-clermontferrand.fr
-
Investigador principal:
- Sandrine CAMPAGNE-LOISEAU, PH
-
Issoire, Francia, 63500
- Aún no reclutando
- Ch Issoire
-
Contacto:
- Aslam MANSOOR
- Correo electrónico: amansoor@ch-issoire.fr
-
Investigador principal:
- Aslam MANSOOR, PH
-
Limoges, Francia, 87042
- Aún no reclutando
- CHU LIMOGES - Hôpital de la mère et de l'Enfant
-
Contacto:
- Tristan GAUTHIER, PhD
- Número de teléfono: +33 (0)5 55 05 61 64
- Correo electrónico: tristan.gauthier@chu-limoges.fr
-
Saint-Etienne, Francia, 42100
- Aún no reclutando
- Clinique Mutualiste de Saint-Etienne
-
Contacto:
- Quentin REBOUL, MD
- Correo electrónico: quentinreboul@free.fr
-
Investigador principal:
- Quentin REBOUL, MD
-
Saint-Etienne, Francia, 42055
- Aún no reclutando
- CHU Saint-Etienne
-
Contacto:
- Céline CHAULEUR, PhD
- Número de teléfono: 0477828383
- Correo electrónico: celine.chauleur@chu-st-etienne.fr
-
Investigador principal:
- Thomas CORSINI
-
Sub-Investigador:
- Céline CHAULEUR
-
Sub-Investigador:
- Ahamd MEDHI
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Any woman received in preoperative consultation in the Gynecology-Obstetrics Department for a benign pathology of a uterus estimated to be large requiring a hysterectomy.
- Patient affiliated or entitled to a social security system
- Patients over 18 years of age
- Patients having given their agreement to participate and after signing the consent form
Exclusion Criteria:
- Woman refusing to participate in the study (lack of consent)
- Non-French speaking woman (unable to conduct a good quality interview of the pregnant woman)
- Participation in another interventional study.
- Patient subject to a legal protection measure or unable to express her consent
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: laparoscopic hysterectomy
Laparoscopic Hysterectomy will be performed in a standardized manner with or without surgical robot |
laparoscopic hysterectomy uses a standardized procedure with or without surgical robot |
|
Experimental: natural vaginal orifice transluminal endoscopic system for hysterectomies (vNOTES)
Vaginal hysterectomy will be performed in a standardized manner using transluminal endoscopic system |
hysterectomy via the vaginal approach by vNOTES (natural vaginal orifice transluminal endoscopic system for hysterectomies) |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Proportion of patient with complications
Periodo de tiempo: From surgery to 6 weeks of surgery
|
The proportion of patients with at least one pre- and post-operative complication at 6 weeks will be estimated along with its 95% confidence interval in each surgical strategy group. The primary endpoint is a composite endpoint including the occurrence of intraoperative and postoperative complications within 6 weeks of surgery. Postoperative complications were Infectious complications, Bleeding complications and All hospital readmissions related to the procedure Postoperative complications will be classified according to the Clavien-Dindo classification Intraoperative complications will be defined as :
|
From surgery to 6 weeks of surgery
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Conversion
Periodo de tiempo: During surgery
|
Number of patients with conversion during surgery |
During surgery
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Post-operative pain
Periodo de tiempo: From surgery to 3 hours of surgery
|
Maximal Pain measured by a numerical scale : 0 no pain / 10 maximum pain |
From surgery to 3 hours of surgery
|
|
Short-term postoperative pain
Periodo de tiempo: From surgery to 1 week after surgery
|
Maximal short-term postoperative pain the first week after surgery measured by a numerical scale (0 no pain / 10 maximum pain) by a daily telephone call |
From surgery to 1 week after surgery
|
|
Duration of postoperative reflex ileus
Periodo de tiempo: Day 0
|
Duration of post-operative reflex ileus between the day of the operation and the resumption of a transit (appearance of the first gas) in hours |
Day 0
|
|
Duration of the operation
Periodo de tiempo: Surgery
|
operative time will be evaluated between the incision and the end of the closure, in minutes. |
Surgery
|
|
Duration of hospitalization and the possibility of returning home
Periodo de tiempo: last day of hospitalization
|
The length of hospital stay will be assessed in days and the possibility of return home by the time in hours from surgical incision to a Chung≥ score of 9/10. The Chung score assesses the possibility of a return home in ambulatory surgery. |
last day of hospitalization
|
|
Sexual dysfunction
Periodo de tiempo: 3 months
|
Sexual disorders: sexual life will be assessed by the difference in the specific validated score (self-questionnaire) (PISQ12 with a score ranging from 0 to 48) between the inclusion date and 3 months after surgery for sexually active women. |
3 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Céline CHAULEUR, PhD, Centre Hospitalier Universitaire de Saint Etienne
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 21PH265
- 2023-A01013-42 (Otro identificador: ANSM)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .